The GLP-1 market has faced supply constraints in recent months as the drugs like Ozempic and Wegovy skyrocket in popularity.
Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections.
Hims & Hers CEO Andrew Dudum told CNBC the company is "confident" that customers will be able to access a consistent supply of the compounded medications.The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — the class of drugs like Ozempic and Wegovy that have skyrocketed in popularity — were not previously offered as part of that program.
The company's oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month. GLP-1s work by mimicking a hormone produced in the gut to tamp down a person's appetite and regulate their blood sugar. When those medications are in shortage, certain manufacturers can prepare a compounded version of them as long as they meet certain requirements from the FDA., the U.S. Food and Drug Administration said patients should not use a compounded GLP-1 drug if an approved drug like Wegovy is available to them.
Technology Internet Enterprise Health Care Industry Hims & Hers Health Inc Andrew Dudum Novo Nordisk A/S Novo Nordisk A/S Business Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
After-hours movers: Palantir, Microchip, Coherent, Hims & Hers HealthAfter-hours movers: Palantir, Microchip, Coherent, Hims & Hers Health
Read more »
Stocks making the biggest moves premarket: Walt Disney, Hims & Hers, Palantir and moreThese are the stocks posting the largest moves in early trading.
Read more »
Hims & Hers CEO walks back supporting campus protests after company stocks tankThe CEO had initially said that there are 'plenty' of companies ready to hire the protesters, 'regardless of university discipline.
Read more »
Hims & Hers CEO walks back praise for anti-Israel protesters after stock dropsHims & Hers founder and CEO Andrew Dudum said Sunday that his earlier comments praising anti-Israel protesters on college campuses were 'misconstrued by some.'
Read more »
Hims & Hers stock slides after CEO's praise for anti-Israel protestersHims & Hers Health stock declined Friday by about 8% after CEO Andrew Dudum's praise for anti-Israel campus protesters in a social media post last week.
Read more »
Hims CEO walks back job offer for campus protesters after stock price tumblesHims stock took a nosedive following the original remark, falling over 8% in a matter of hours.
Read more »